Reports
Sale
Australia and New Zealand In Vitro Diagnostics Market Size: By Technology: Clinical Chemistry, Molecular Diagnostics, Immuno Diagnostics, Hematology, Others; By Product and Services: Instruments, Reagents and Kits, Services, Data Management Software; By Applications; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Australia and New Zealand In Vitro Diagnostics Market Outlook
The Australia and New Zealand in vitro diagnostics market size is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, driven by rising technical advancements to develop new diagnostic tools along with increasing expenditures and investments in the healthcare domain across the region.
Australia and New Zealand In Vitro Diagnostics Market Overview
The in vitro diagnostics market in Australia and New Zealand has witnessed significant growth driven owing to factors like advancements in diagnostic techniques and increasing adoption of molecular diagnostics, point of care testing and digital technologies to offer early detection and prevention of diseases. In 2023, around 154,000 new cancer cases are expected to be diagnosed in the Australian population. As in vitro diagnostics find its application in cancer detection, the Australia and New Zealand in vitro diagnostics market demand is predicted to grow in the coming years.
The market is further driven by the increased government efforts to offer awareness on early diagnosis and preventive healthcare. The region has been witnessing a significant surge in investments to improve and upgrade the diagnostic facilities as well.
Surge in Research and Development Activities to Develop New Diagnostic Devices
In September 2023, the scientists of Peter Doherty Institute for Infection and Immunity (Doherty Institute) and WEHI (Walter and Eliza Hall Institute of Medical Research) developed MPXV-CRISPR, the first CRISPR based diagnostic tool to detect monkeypox virus (MPXV) in clinical samples. Leveraging the extremely sensitive and powerful technology, the diagnostic tool is designed to target genetic sequences present exclusively in MPXV. The advent of the novel tool can be a breakthrough to help in monkey pox infection detection and treatment as the conventional lab tests take multiple days to provide results. The increasing emphasis on preventing the spread of infectious diseases, especially after the sudden outbreak of COVID-19 is anticipated to bolster the Australia and New Zealand in vitro diagnostics market growth in upcoming years.
Growth in Government Investments
In June 2023, the Australian Government granted USD 73 million to upgrade and implement new medical technologies across the region. The investment was divided into 19 different projects wherein, around USD 9.8 million was aimed at offering cancer treatment with the Targeted Alpha Therapy and around USD 2.9 million was set aside to support Australia’s first human microbiome bank. The investment is poised to help the scientists with research and development to develop better solutions for fatal diseases. In addition, increased investments from private ventures and other entities are also expected to increase the Australia and New Zealand in vitro diagnostics market size.
Rising Prevalence for Remote Test Kits
In July 2023, Trajan Scientific and Medical registered a collection of Neoteryx’s remote micro sampling devices and test kits. Mitra® has been classified as Class I in vitro diagnostic (IVD) medical device by the Therapeutic Goods Administration (TGA) in Australia while Mitra® Sample Collection Kit has been titled as a Class IIa medical device for home use. Contributing to the emerging trend of telehealth and remote monitoring, the devices are expected to boost the Australia and New Zealand in vitro diagnostics market share by offering personalized solutions to the patients. The devices offer self-guided specimen collection, owing to its easy to use and finger stick method. Specimens collected through the devices have been used to examine antibodies against SARS-CoV-2, inflammatory biomarkers, PSA for prostate cancer screenings, and more.
Australia and New Zealand In Vitro Diagnostics Market Segmentation
Market Breakup by Technology
- Clinical Chemistry
- Molecular Diagnostics
- Immuno Diagnostics
- Hematology
- Others
Market Breakup by Product and Services
- Instruments
- Reagents and Kits
- Services
- Data Management Software
Market Breakup by Applications
- Infectious Disease
- Diabetes
- Cancer/Oncology
- Cardiology
- Autoimmune Disease
- Other Applications
Market Breakup by End User
- Diagnostic Laboratories
- Hospitals and Clinics
- Academic Institutes
- Point-of-Care Testing centers
- Others
Market Breakup by Country
- Australia
- New Zealand
Australia and New Zealand In Vitro Diagnostics Market Regional Analysis
In the forecast period, Australia is expected to lead the market for in vitro diagnostics, which can be attributed to the rising investments in the healthcare medical infrastructure. In March 2023, researchers from the University of Sydney were awarded USD 47 million to support their investigations on younger onset-dementia and treatment of blinding eye diseases through stem cell therapies. The Government of Australia also presented their support for enhanced research activities by launching the Medical Research Future Fund (MRFF) grant.
With the rising prevalence of geriatric population and a surge in budding technology driven start-ups, the market is likely to witness further growth.
New Zealand is also predicted to witness significant growth. In December 2022, Pictor, a New Zealand based start-up, expanded their product pipeline to apply cost effective, accurate, and prompt testing services for diseases by deploying multiple innovative approaches. The start-up raised USD 5 million and successfully launched PictArray SARS-CoV-2 IgG Antibody Test.
Australia and New Zealand In Vitro Diagnostics Market: Competitor Landscape
In December 2023, the Bridgewest Group announced their expansion of biomedical operations in Bentley, Perth with the help of USD 2 million investment from the Western Australian Government. The expansion is aimed at boosting local manufacturing of several medical products along with the installation of new automated blow, fill, and seal line of products. Apart from boosting the infrastructure and facilities, the initiative is expected to offer 400 jobs to the local community, boosting the overall economy as well. The market has been experiencing similar investment initiatives and partnerships to enhance the quality of solutions and facilities being offered to the patients.
The key features of the Australia and New Zealand in vitro diagnostics market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- BioMerieux SA
- F. Hoffmann-La Roche Ltd
- Becton, Dickinson and Company
- Bio-Rad Laboratories Inc.
- Abbott Laboratories, Inc.
- Siemens AG
- Thermo Fisher Scientific, Inc.
- QIAGEN N.V.
- Roche Diagnostics
- Danaher Corporation
- Agilent Technologies, Inc
- Quidel Corporation
- Diasorin S.P.A
- Illumina, Inc.
- Hologic, Inc
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Technology |
|
| Breakup by Product and Services |
|
| Breakup by Applications |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Australia and New Zealand In Vitro Diagnostics Market Overview
3.1 Australia and New Zealand In Vitro Diagnostics Market Historical Value (2017-2023)
3.2 Australia and New Zealand In Vitro Diagnostics Market Forecast Value (2024-2032)
4 Australia and New Zealand In Vitro Diagnostics Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Australia and New Zealand In Vitro Diagnostics Market Segmentation
5.1 Australia and New Zealand In Vitro Diagnostics Market by Technology
5.1.1 Market Overview
5.1.2 Clinical Chemistry
5.1.3 Molecular Diagnostics
5.1.4 Immuno Diagnostics
5.1.5 Hematology
5.1.6 Others
5.2 Australia and New Zealand In Vitro Diagnostics Market by Product and Services
5.2.1 Market Overview
5.2.2 Instruments
5.2.3 Reagents and Kits
5.2.4 Services
5.2.5 Data Management Software
5.3 Australia and New Zealand In Vitro Diagnostics Market by Applications
5.3.1 Market Overview
5.3.2 Infectious Disease
5.3.3 Diabetes
5.3.4 Cancer/Oncology
5.3.5 Cardiology
5.3.6 Autoimmune Disease
5.3.7 Other Applications
5.4 Australia and New Zealand In Vitro Diagnostics Market by End User
5.4.1 Market Overview
5.4.2 Diagnostic Laboratories
5.4.3 Hospitals and Clinics
5.4.4 Academic Institutes
5.4.5 Point-of-Care Testing centers
5.4.6 Others
5.5 Australia and New Zealand In Vitro Diagnostics Market by Country
5.5.1 Market Overview
5.5.2 Australia
5.5.3 New Zealand
6 Patent Analysis
6.1 Analysis by Type of Patent
6.2 Analysis by Publication year
6.3 Analysis by Issuing Authority
6.4 Analysis by Patent Age
6.5 Analysis by CPC Analysis
6.6 Analysis by Patent Valuation
6.7 Analysis by Key Players
7 Grants Analysis
7.1 Analysis by year
7.2 Analysis by Amount Awarded
7.3 Analysis by Issuing Authority
7.4 Analysis by Grant Application
7.5 Analysis by Funding Institute
7.6 Analysis by NIH Departments
7.7 Analysis by Recipient Organization
8 Funding Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Partnership and Collaborations Analysis
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Partnership
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Regulatory Framework
10.1 Regulatory Overview
11 Supplier Landscape
11.1 BioMerieux SA
11.1.1 Financial Analysis
11.1.2 Product Portfolio
11.1.3 Demographic Reach and Achievements
11.1.4 Mergers and Acquisitions
11.1.5 Certifications
11.2 F. Hoffmann-La Roche Ltd
11.2.1 Financial Analysis
11.2.2 Product Portfolio
11.2.3 Demographic Reach and Achievements
11.2.4 Mergers and Acquisitions
11.2.5 Certifications
11.3 Becton, Dickinson and Company
11.3.1 Financial Analysis
11.3.2 Product Portfolio
11.3.3 Demographic Reach and Achievements
11.3.4 Mergers and Acquisitions
11.3.5 Certifications
11.4 Bio-Rad Laboratories Inc.
11.4.1 Financial Analysis
11.4.2 Financial Portfolio
11.4.3 Demographic Reach and Achievements
11.4.4 Mergers and Acquisitions
11.4.5 Certifications
11.5 Abbott Laboratories, Inc.
11.5.1 Financial Analysis
11.5.2 Product Portfolio
11.5.3 Demographic Reach and Achievements
11.5.4 Mergers and Acquisitions
11.5.5 Certifications
11.6 Siemens AG
11.6.1 Financial Analysis
11.6.2 Product Portfolio
11.6.3 Demographic Reach and Achievements
11.6.4 Mergers and Acquisitions
11.6.5 Certifications
11.7 Thermo Fisher Scientific, Inc.
11.7.1 Financial Analysis
11.7.2 Product Portfolio
11.7.3 Demographic Reach and Achievements
11.7.4 Mergers and Acquisitions
11.7.5 Certifications
11.8 QIAGEN N.V.
11.8.1 Financial Analysis
11.8.2 Product Portfolio
11.8.3 Demographic Reach and Achievements
11.8.4 Mergers and Acquisitions
11.8.5 Certifications
11.9 Roche Diagnostics
11.9.1 Financial Analysis
11.9.2 Product Portfolio
11.9.3 Demographic Reach and Achievements
11.9.4 Mergers and Acquisitions
11.9.5 Certifications
11.10 Danaher Corporation
11.10.1 Financial Analysis
11.10.2 Product Portfolio
11.10.3 Demographic Reach and Achievements
11.10.4 Mergers and Acquisitions
11.10.5 Certifications
11.11 Agilent Technologies, Inc
11.11.1 Financial Analysis
11.11.2 Product Portfolio
11.11.3 Demographic Reach and Achievements
11.11.4 Mergers and Acquisitions
11.11.5 Certifications
11.12 Quidel Corporation
11.12.1 Financial Analysis
11.12.2 Product Portfolio
11.12.3 Demographic Reach and Achievements
11.12.4 Mergers and Acquisitions
11.12.5 Certifications
11.13 Diasorin S.P.A
11.13.1 Financial Analysis
11.13.2 Product Portfolio
11.13.3 Demographic Reach and Achievements
11.13.4 Mergers and Acquisitions
11.13.5 Certifications
11.14 Illumina, Inc.
11.14.1 Financial Analysis
11.14.2 Product Portfolio
11.14.3 Demographic Reach and Achievements
11.14.4 Mergers and Acquisitions
11.14.5 Certifications
11.15 Hologic, Inc
11.15.1 Financial Analysis
11.15.2 Product Portfolio
11.15.3 Demographic Reach and Achievements
11.15.4 Mergers and Acquisitions
11.15.5 Certifications
12 Australia and New Zealand In Vitro Diagnostics Market - Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Key Opinion Leaders (KOL) Insights (Additional Insight)
14 Company Competitiveness Analysis (Additional Insight)
14.1 Very Small Companies
14.2 Small Companies
14.3 Mid-Sized Companies
14.4 Large Companies
14.5 Very Large Companies
15 Payment Methods (Additional Insight)
15.1 Government Funded
15.2 Private Insurance
15.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032, likely to be driven by increasing technical advancements to develop new diagnostic tools along with growing expenditures and government investments in the healthcare domain across the region.
The market demand is driven by the rising prevalence of chronic diseases in the region, owing to an aging population along with rising emphasis on improving the medical research infrastructure.
The growing advancements in upgrading and launching new research facilities is a major market trend. In September 2023, the Australian scientists developed MPXV-CRISPR, the first CRISPR based diagnostic tool to detect monkeypox virus (MPXV) in clinical samples.
Based on technology, the market is divided into clinical chemistry, molecular diagnostics, immuno diagnostics, and hematology, among others.
Major end users include diagnostic laboratories, hospitals and clinics, academic institutes, and point-of-care testing centres, among others.
Instruments, reagents and kits, services, and data management software are common products and services available in the market.
Common application areas include infectious disease, diabetes, cancer/oncology, cardiology, and autoimmune disease, among others.
Based on countries, it includes Australia and New Zealand.
Key players involved in the market are BioMerieux SA., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Abbott Laboratories, Inc., Siemens AG, Thermo Fisher Scientific, Inc., QIAGEN N.V., Roche Diagnostics, Danaher Corporation, Agilent Technologies, Inc., Diasorin S.P.A, Illumina, Inc., Hologic, Inc., and Quidel Corporation.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2199
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 3299
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 4399
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 5499
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER